Related Experiment Video
Updated: Mar 10, 2026
03:26
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
Published on: August 28, 2020
2.4K
Jejunitis secondary to Duodopa® probe, a different complication.
Marta Magaz Martínez1, José Luis Martínez Porras2, Borja Oliva2
1Aparato Digestivo, Hospital Universitario Puerta de Hierro Majadahonda. Madrid, ESPAÑA.
Revista Espanola De Enfermedades Digestivas
|December 10, 2016
Summary
Continuous intraduodenal levodopa/carbidopa infusion for advanced Parkinson's disease can rarely cause jejunitis due to phytobezoars. Prompt probe removal and replacement effectively resolves this complication.
Area of Science:
- Gastroenterology
- Neurology
- Medical Devices
Background:
- Continuous intraduodenal levodopa/carbidopa infusion (Duodopa®) is a treatment for advanced Parkinson's disease unresponsive to conventional therapies.
- This delivery method involves a probe placed for sustained drug delivery.
Observation:
- A patient receiving intraduodenal levodopa/carbidopa infusion developed jejunitis.
- A distal phytobezoar (a mass of undigested plant material) was identified as the primary cause of the jejunitis.
Findings:
- Phytobezoar formation is a rare complication associated with intraduodenal infusion probes.
- Intestinal hypomotility may be a predisposing factor for phytobezoar development in these patients.
Implications:
- Early recognition and management of phytobezoar-induced jejunitis are crucial.
- Prompt removal of the affected probe and insertion of a new one can lead to resolution of the complication.
- This case highlights the importance of considering rare gastrointestinal complications in patients with advanced Parkinson's disease undergoing specialized infusion therapies.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
517
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
517
01:17Drugs for Treatment of Diarrhea-Predominant IBS
821
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
821
01:25Urinary Tract Infection II: Pathophysiology
980
The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...
980
01:20Disorders of the Urinary System
1.4K
The urinary system is responsible for eliminating waste and excess fluids from the body. However, disorders of the urinary system can arise due to various reasons like infections, stress, age, congenital abnormalities, and lifestyle.
Urinary tract infections (UTIs) are one of the most common urinary system disorders. They are caused by bacteria that enter the urethra and can spread to the bladder resulting in cystitis. Pyelonephritis is the result of a UTI that has ascended to the level of the...
Urinary tract infections (UTIs) are one of the most common urinary system disorders. They are caused by bacteria that enter the urethra and can spread to the bladder resulting in cystitis. Pyelonephritis is the result of a UTI that has ascended to the level of the...
1.4K